Literature DB >> 32200657

State-of-the-art treatment strategies for nontuberculous mycobacteria infections.

Maria-Carmen Muñoz-Egea1, Nerea Carrasco-Antón2, Jaime Esteban1.   

Abstract

INTRODUCTION: Non-tuberculous Mycobacteria (NTM) are a group of organisms whose importance in medicine seems to be increasing in recent times. The increasing number of patients susceptible to these diseases make it necessary to expand our knowledge of therapeutic options and to explore future possibilities for the development of a therapeutic arsenal. AREAS COVERED: In this review, the authors provide a brief introduction about the present importance of NTM and describe the present recommendations of the available guidelines for their treatment. They include a description of the future options for the management of these patients, especially focusing on new antibiotics. The authors also look at possibilities for future therapeutic options, such as antibiofilm strategies. EXPERT OPINION: No actual changes have been made to the current recommendations for the management of most NTM infections (except perhaps the availability of nebulized amikacin). However, it is also true that we have increased the number of available antibiotic treatment options with good in vitro activity against NTM. The use of these drugs in selected cases could increase the therapeutic possibilities. However, some problems are still present, such as the knowledge of the actual meaning of a NTM isolate, and will probably be a key part of future research.

Entities:  

Keywords:  Non-tuberculous mycobacteria; amikacin; bedaquiline; clofazimine; delamanid; guidelines; macrolides; omadacycline; tedizolid; tigecycline; treatment

Mesh:

Substances:

Year:  2020        PMID: 32200657     DOI: 10.1080/14656566.2020.1740205

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  5 in total

1.  Activity of Antibiotics and Potential Antibiofilm Agents against Biofilm-Producing Mycobacterium avium-intracellulare Complex Causing Chronic Pulmonary Infections.

Authors:  Elena Portell-Buj; Cecibel González-Criollo; Alexandre López-Gavín; Mariana Fernández-Pittol; Maria Antònia Busquets; Joan Estelrich; Montserrat Garrigó; Marc Rubio; Griselda Tudó; Julian Gonzalez-Martin
Journal:  Antibiotics (Basel)       Date:  2022-04-27

Review 2.  Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections.

Authors:  Jan-Willem Alffenaar; Anne-Grete Märtson; Scott K Heysell; Jin-Gun Cho; Asad Patanwala; Gina Burch; Hannah Y Kim; Marieke G G Sturkenboom; Anthony Byrne; Debbie Marriott; Indy Sandaradura; Simon Tiberi; Vitali Sintchencko; Shashikant Srivastava; Charles A Peloquin
Journal:  Clin Pharmacokinet       Date:  2021-03-10       Impact factor: 6.447

Review 3.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

Review 4.  Considerations for Phage Therapy Against Mycobacterium abscessus.

Authors:  Abrar Senhaji-Kacha; Jaime Esteban; Meritxell Garcia-Quintanilla
Journal:  Front Microbiol       Date:  2021-01-18       Impact factor: 5.640

5.  Central nervous system infection caused by Mycobacterium houstonense: A case report.

Authors:  LiXia Wang; FaPing Wang; Chuan Yang; FengMing Luo
Journal:  Front Neurol       Date:  2022-09-01       Impact factor: 4.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.